Gene info: ID 151

Gene: ADRA2B

GENE ID: 151

Description: adrenoceptor alpha 2B

Gene type: protein-coding

Location: 2q11.2

dbXrefs: Ensembl:ENSG00000274286 MIM:104260 Vega:OTTHUMG00000188276 UniprotKB:P18089

RefSeq: NG_032950.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 2.156e-1 (AD) 7.322e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
NGFR	0.632
BEST1	0.607
RGS3	0.604
SLC26A9	0.593
SNAI1	0.587
PHF19	0.583
TFEB	0.58
H2AFJ	0.577
SYNE3	0.57
NUAK2	0.566

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
VIP	-0.401
HAPLN1	-0.397
FAM19A2	-0.382
CUX2	-0.379
IGF1	-0.377
DLX1	-0.377
BEAN1	-0.368
SERTM1	-0.367
CNTN5	-0.366
VWC2	-0.355

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00246	Ziprasidone	Small Molecule	146939-27-7	Approved	Target
DB00248	Cabergoline	Small Molecule	81409-90-7	Approved	Target
DB00268	Ropinirole	Small Molecule	91374-21-9	Approved\|Investigational	Target
DB00292	Etomidate	Small Molecule	33125-97-2	Approved	Target
DB00334	Olanzapine	Small Molecule	132539-06-1	Approved\|Investigational	Target
DB00363	Clozapine	Small Molecule	5786-21-0	Approved	Target
DB00368	Norepinephrine	Small Molecule	51-41-2	Approved	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00413	Pramipexole	Small Molecule	104632-26-0	Approved\|Investigational	Target
DB00457	Prazosin	Small Molecule	19216-56-9	Approved	Target
DB00484	Brimonidine	Small Molecule	59803-98-4	Approved	Target
DB00575	Clonidine	Small Molecule	4205-90-7	Approved	Target
DB00589	Lisuride	Small Molecule	18016-80-3	Approved\|Investigational	Target
DB00629	Guanabenz	Small Molecule	5051-62-7	Approved\|Investigational	Target
DB00668	Epinephrine	Small Molecule	51-43-4	Approved	Target
DB00696	Ergotamine	Small Molecule	113-15-5	Approved	Target
DB00697	Tizanidine	Small Molecule	51322-75-9	Approved\|Investigational	Target
DB00714	Apomorphine	Small Molecule	58-00-4	Approved\|Investigational	Target
DB00726	Trimipramine	Small Molecule	739-71-9	Approved	Target
DB00734	Risperidone	Small Molecule	106266-06-2	Approved\|Investigational	Target
DB00797	Tolazoline	Small Molecule	59-98-3	Approved	Target
DB00800	Fenoldopam	Small Molecule	67227-56-9	Approved	Target
DB00925	Phenoxybenzamine	Small Molecule	59-96-1	Approved	Target
DB00935	Oxymetazoline	Small Molecule	1491-59-4	Approved\|Investigational	Target
DB00964	Apraclonidine	Small Molecule	66711-21-5	Approved	Target
DB01018	Guanfacine	Small Molecule	29110-47-2	Approved\|Investigational	Target
DB01136	Carvedilol	Small Molecule	72956-09-3	Approved\|Investigational	Target
DB01142	Doxepin	Small Molecule	1668-19-5	Approved\|Investigational	Target
DB01186	Pergolide	Small Molecule	66104-22-1	Approved\|Investigational\|Withdrawn	Target
DB01200	Bromocriptine	Small Molecule	25614-03-3	Approved\|Investigational	Target
DB01224	Quetiapine	Small Molecule	111974-69-7	Approved	Target
DB01238	Aripiprazole	Small Molecule	129722-12-9	Approved\|Investigational	Target
DB01267	Paliperidone	Small Molecule	144598-75-4	Approved	Target
DB01363	Ephedra	Small Molecule	-	Approved\|Nutraceutical\|Withdrawn	Target
DB01392	Yohimbine	Small Molecule	146-48-5	Approved\|Investigational	Target
DB01403	Methotrimeprazine	Small Molecule	60-99-1	Approved\|Investigational	Target
DB01577	Methamphetamine	Small Molecule	537-46-2	Approved\|Illicit	Target
DB04855	Dronedarone	Small Molecule	141626-36-0	Approved	Target
DB05271	Rotigotine	Small Molecule	99755-59-6	Approved	Target
DB05461	OPC-28326	Small Molecule	-	Investigational	Target
DB05492	Epicept NP-1	Small Molecule	-	Investigational	Target
DB06148	Mianserin	Small Molecule	24219-97-4	Approved\|Investigational	Target
DB06216	Asenapine	Small Molecule	65576-45-6	Approved	Target
DB06229	Ocaperidone	Small Molecule	129029-23-8	Investigational	Target
DB06262	Droxidopa	Small Molecule	23651-95-8	Approved\|Investigational	Target
DB06694	Xylometazoline	Small Molecule	526-36-3	Approved\|Investigational	Target
DB11124	Racepinephrine	Small Molecule	329-65-7	Approved	Target
DB00217	Bethanidine	Small Molecule	55-73-2	Approved	Target
DB00397	Phenylpropanolamine	Small Molecule	14838-15-4	Approved\|Withdrawn	Target
DB00477	Chlorpromazine	Small Molecule	50-53-3	Approved\|Investigational	Target
DB00540	Nortriptyline	Small Molecule	72-69-5	Approved	Target
DB00543	Amoxapine	Small Molecule	14028-44-5	Approved	Target
DB00841	Dobutamine	Small Molecule	34368-04-2	Approved	Target
DB00934	Maprotiline	Small Molecule	10262-69-8	Approved\|Investigational	Target
DB01049	Ergoloid mesylate	Small Molecule	8067-24-1	Approved	Target
DB01151	Desipramine	Small Molecule	50-47-5	Approved\|Investigational	Target
DB06678	Esmirtazapine	Small Molecule	61337-87-9	Investigational	Target
DB06707	Levonordefrin	Small Molecule	829-74-3	Approved	Target
DB09167	Dosulepin	Small Molecule	113-53-1	Approved	Target
DB09194	Etoperidone	Small Molecule	52942-31-1	Withdrawn	Target
DB09195	Lorpiprazole	Small Molecule	108785-69-9	Approved	Target
DB09202	Cirazoline	Small Molecule	59939-16-1	Experimental	Target
DB09304	Setiptiline	Small Molecule	57262-94-9	Approved	Target
DB13025	Tiapride	Small Molecule	51012-32-9	Approved\|Investigational	Target
DB00182	Amphetamine	Small Molecule	300-62-9	Approved\|Illicit\|Investigational	Target
DB01365	Mephentermine	Small Molecule	100-92-5	Approved	Target
DB09205	Moxisylyte	Small Molecule	54-32-0	Approved\|Investigational	Target
DB09229	Aranidipine	Small Molecule	86780-90-7	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C058525	2-methoxyidazoxan	ADRA2B protein binds to 2-methoxyidazoxan	20030735
C058525	2-methoxyidazoxan	Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Oxymetazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	xylometazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
D000082	Acetaminophen	Acetaminophen results in decreased expression of ADRA2B mRNA	22230336
D000109	Acetylcholine	ADRA2B protein affects the susceptibility to [Phenylephrine co-treated with Acetylcholine]	16815979
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of ADRA2B gene	27153756
C014983	amitraz	amitraz results in decreased activity of ADRA2B protein	21251949
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ADRA2B mRNA	16483693
C032994	AR-C239	AR-C239 binds to and results in decreased activity of ADRA2B protein	15265636
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of ADRA2B mRNA	19128835
D001280	Atrazine	Atrazine results in decreased expression of ADRA2B mRNA	25929836
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of ADRA2B mRNA	20064835
C006780	bisphenol A	bisphenol A results in increased expression of ADRA2B mRNA	27685785
C018475	butyraldehyde	butyraldehyde results in increased expression of ADRA2B mRNA	26079696
D002104	Cadmium	Cadmium results in increased expression of ADRA2B mRNA	23369406
D002118	Calcium	[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D002118	Calcium	[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D002118	Calcium	[Oxymetazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D002118	Calcium	[xylometazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of ADRA2B mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of ADRA2B protein	12629582
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2B protein	10217548
D003471	Cuprizone	Cuprizone results in increased expression of ADRA2B mRNA	27523638
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of ADRA2B mRNA	15620428
D004026	Dieldrin	Dieldrin results in decreased expression of ADRA2B mRNA	18812211
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of ADRA2B mRNA	28085963
D004837	Epinephrine	ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]	17680988
D004837	Epinephrine	ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]	17680988
D004837	Epinephrine	ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]	17680988
D004837	Epinephrine	ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]	17680988
D004837	Epinephrine	Epinephrine binds to and results in increased activity of ADRA2B protein	20030735
D004837	Epinephrine	[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D004837	Epinephrine	Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of ADRA2B gene	16495775
C069837	fullerene C60	fullerene C60 results in decreased expression of ADRA2B mRNA	19167457
C008261	lead acetate	lead acetate results in increased expression of ADRA2B mRNA	21829687
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of ADRA2B mRNA	24810058
C028007	nickel monoxide	nickel monoxide results in decreased expression of ADRA2B mRNA	19167457
D009638	Norepinephrine	Norepinephrine binds to and results in increased activity of ADRA2B protein	20030735
D009638	Norepinephrine	[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D009638	Norepinephrine	Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
C106996	NRA 0045	NRA 0045 binds to ADRA2B protein	9223539
D010100	Oxygen	Oxygen deficiency results in increased expression of ADRA2B mRNA	20880076
D010109	Oxymetazoline	Oxymetazoline binds to and results in increased activity of ADRA2B protein	20030735
D010109	Oxymetazoline	[Oxymetazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
D010109	Oxymetazoline	Oxymetazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735
C046012	pentanal	pentanal results in increased expression of ADRA2B mRNA	26079696
D010656	Phenylephrine	ADRA2B protein affects the susceptibility to Phenylephrine	16815979
D010656	Phenylephrine	ADRA2B protein affects the susceptibility to [Phenylephrine co-treated with Acetylcholine]	16815979
D010936	Plant Extracts	Plant Extracts results in decreased expression of ADRA2B mRNA	23557933
D059808	Polyphenols	Polyphenols results in decreased expression of ADRA2B mRNA	16293270
C513635	S-2-pentyl-4-pentynoic hydroxamic acid	S-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of ADRA2B mRNA	21427059
D013629	Tamoxifen	Tamoxifen results in increased expression of ADRA2B mRNA	25123088
C031324	tris(chloroethyl)phosphate	tris(chloroethyl)phosphate results in increased expression of ADRA2B mRNA	27776230
D014635	Valproic Acid	Valproic Acid results in increased methylation of ADRA2B gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of ADRA2B mRNA	21427059
D014640	Vancomycin	Vancomycin results in increased expression of ADRA2B mRNA	18930951
C029297	vinylidene chloride	vinylidene chloride results in decreased expression of ADRA2B mRNA	26682919
C009695	xylometazoline	xylometazoline binds to and results in increased activity of ADRA2B protein	20030735
C009695	xylometazoline	[xylometazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium	20030735
C009695	xylometazoline	xylometazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]	20030735

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004935	adrenergic receptor activity	-	IBA	21873635
GO:0004938	alpha2-adrenergic receptor activity	-	IDA	17215105
GO:0005515	protein binding	-	IPI	16531006 23105096 24114805
GO:0051379	epinephrine binding	-	IDA	17215105

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000187	activation of MAPK activity	-	IEA	-
GO:0003056	regulation of vascular smooth muscle contraction	-	IEA	-
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007188	adenylate cyclase-modulating G-protein coupled receptor signaling pathway	-	IBA	21873635
GO:0007267	cell-cell signaling	-	IBA	21873635
GO:0007267	cell-cell signaling	-	TAS	2164221
GO:0007565	female pregnancy	-	IEA	-
GO:0010700	negative regulation of norepinephrine secretion	-	NAS	16531006
GO:0010700	negative regulation of norepinephrine secretion	-	TAS	19477270
GO:0030168	platelet activation	-	IEA	-
GO:0032148	activation of protein kinase B activity	-	IDA	17215105
GO:0032811	negative regulation of epinephrine secretion	-	NAS	16531006
GO:0035625	epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway	-	IDA	17215105
GO:0043410	positive regulation of MAPK cascade	-	IDA	17215105
GO:0045666	positive regulation of neuron differentiation	-	IDA	17215105
GO:0045777	positive regulation of blood pressure	-	IEA	-
GO:0070474	positive regulation of uterine smooth muscle contraction	-	IEA	-
GO:0071875	adrenergic receptor signaling pathway	-	IDA	17215105
GO:0071880	adenylate cyclase-activating adrenergic receptor signaling pathway	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005622	intracellular	-	IEA	-
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0005887	integral component of plasma membrane	-	TAS	2164221

KEGG ID	KEGG Term
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375280	Amine ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-390696	Adrenoceptors	TAS
R-HSA-392023	Adrenaline signalling through Alpha-2 adrenergic receptor	TAS
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-418597	G alpha (z) signalling events	TAS
R-HSA-500792	GPCR ligand binding	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76009	Platelet Aggregation (Plug Formation)	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
16907703	Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study. (2006 Sep)	Wilk JB	Ann Hum Genet